This trial is evaluating whether Alternate day fasting will improve 1 primary outcome and 16 secondary outcomes in patients with Obesity. Measurement will happen over the course of Change from week 1 to week 12.
This trial requires 80 total participants across 4 different treatment groups
This trial involves 4 different treatments. Alternate Day Fasting is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"This is the first study to identify that lifestyle modifications and exercise training are the treatment choice in patients with NASH. The present study also suggested that other therapy strategies should be established to further improve its quality of life." - Anonymous Online Contributor
"Chronic liver disease can be cured. However, the best long-term outcomes depend largely on management of the underlying metabolic syndrome and lifestyle factors. Lifestyle changes are important in the treatment of nonalcoholic steatohepatitis." - Anonymous Online Contributor
"The association between obesity and nonalcoholic steatohepatitis suggests common genetic or environmental factors. The association of nonalcoholic steatohepatitis with insulin resistance is consistent with the hypothesis that hepatic steatosis may lead to insulin resistance through various mediations. Prospective studies of the development of insulin resistance and fat accumulation throughout the liver throughout the life course, with follow-up of those with steatohepatitis, are needed to determine the role of steatosis in developing insulin resistance and associated metabolic disorders." - Anonymous Online Contributor
"At least 2.3 million people have NASH in the United States. The prevalence of NASH in this study is slightly higher than in most other studies with most studies in the United States reporting prevalences of approximately 2.0% to 2.5% of the general population." - Anonymous Online Contributor
"In patients with NASH, liver disease can be detected by an elevated alanine aminotransferase and bilirubin levels. Ultrasonographic features of nonalcoholic steatohepatitis can be identified, but cholestasis is not evident." - Anonymous Online Contributor
"Liver biopsies performed for all clinical indications (including ALD, chronic viral hepatitis, autoimmune diseases, HBV, HCV, metastatic and hepatocellular carcinoma) are of great value for identifying nonalcoholic fatty liver disease. This is a condition with diverse histological subtypes that, if left untreated leads to a significant increase in mortality and morbidity rates, since nonalcoholic steatohepatitis is associated with increased risk of hepatic fibrosis and cirrhosis, cardiovascular disease, and complications in the skeletal muscle. Thus, nonalcoholic steatohepatitis requires special attention since its histological sub-type has been demonstrated to cause significant increase mortality in certain sub-populations." - Anonymous Online Contributor
"Alternating-day fasting can have a beneficial effect on glycaemic control and lipid metabolism but does not seem to change hepatic insulin sensitivity. This trial is registered at clinicaltrials.gov: NCT00267725." - Anonymous Online Contributor
"The new method of AF is not associated with serious adverse outcomes in this heterogeneous study, including patients having a history of obesity. Clinicians might consider switching to this less restrictive, healthier method of losing weight." - Anonymous Online Contributor
"ADF is well tolerated, does not adversely affect hepatic biochemistry or liver function, and is capable of reversing abnormal hepatic profiles in patients with nonalcoholic fatty liver disease with or without steatohepatitis, particularly if the individual treatment is long term." - Anonymous Online Contributor
"There is a general consensus within the NAFLD community that NASH should fall within the specialty of internists (generalists are not well suited for NASH treatment and it's associated complications). However, this consensus is not strong enough to recommend that the majority of patients with NASH participate in a clinical trial vs. a traditional treatment approach (e.g. nonclective drug therapies in a primary care setting)." - Anonymous Online Contributor
"Obesity and metabolic syndrome increased the risk of developing NAFLD in first degree relatives. Further studies are required to understand the interaction between metabolic syndrome and NAFLD." - Anonymous Online Contributor
"ADF might be a therapeutic option with the potential to improve patient quality of life through alleviation of symptoms and discomfort associated with hepatic steatosis, and should prompt further research on its potential benefits." - Anonymous Online Contributor